Appetite suppression from retatrutide typically begins within the first week and intensifies as the dose titrates upward
Retatrutide primarily operates on a systemic, hormonal level, influencing appetite, satiety, and glucose regulation through its triple agonism of GIP, GLP-1, and glucagon receptors
Eli Lilly's next-generation obesity treatment "retatrutide" has ignited competition for next-generation obesity drugs, confirming a weight loss effect of up to 28% in phase 3 clinical trials
Regardless, eating enough protein plus strength training is absolutely critical for people taking a GLP-1 medicines
monitor INR levels
Clinical trials have shown promising results, with many participants experiencing significant weight loss and improvements in metabolic markers